Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Theranexus SA ( (FR:ALTHX) ) has shared an update.
Theranexus has reported a strengthened cash position of €4.0 million as of January 2025, up from €1.0 million in December 2024, following an upfront payment from Exeltis and funding from Bpifrance. The company has achieved a significant milestone with its partnership with Insud Pharma/Exeltis for the development of TX01 for Niemann-Pick type C and Gaucher diseases, extending its financial horizon to the first quarter of 2026. Additionally, Theranexus is exploring options for launching a pivotal trial for its Batten-1 drug candidate and continues its research on a novel antisense oligonucleotide targeting TFEB for rare neurological diseases.
More about Theranexus SA
Theranexus is an innovative biopharmaceutical company originating from the French Alternative Energies and Atomic Energy Commission (CEA). It specializes in identifying and characterizing advanced therapy drug candidates for rare neurological disorders and has a drug candidate in clinical development for Batten disease. The company is listed on the Euronext Growth market in Paris.
YTD Price Performance: 5.19%
Average Trading Volume: 4,497
Technical Sentiment Consensus Rating: Hold
Current Market Cap: €4.16M
Find detailed analytics on ALTHX stock on TipRanks’ Stock Analysis page.
